Pharmaxis Ltd
ASX:PXS
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Pharmaxis Ltd
ASX:PXS
|
15.1m AUD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1.1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
564.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
282.5B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.9B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
226B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.5B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.2B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
98.3B EUR |
Loading...
|
Market Distribution
| Min | -16 177 900% |
| 30th Percentile | -544.7% |
| Median | -27.7% |
| 70th Percentile | 3.1% |
| Max | 3 174 540% |
Other Profitability Ratios
Pharmaxis Ltd
Glance View
Pharmaxis Ltd. is a pharmaceutical research company, which engages in the development and commercialization of therapeutic products for chronic respiratory disorders, autoimmune diseases, and improved lung function test. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. The firm has two approved respiratory products, Bronchitol and Aridol. The Bronchitol is used for the treatment of cystic fibrosis to help patient’s clear mucus from their lungs. Aridol is a lung function test designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The firm's development pipeline assets include a topical pan-Lysyl Oxidase (LOX) inhibitor in development for scar revision, keloid scarring and scarring from burn wounds; a series of Lysyl Oxidase Like 2 (LOXL2) inhibitors targeting fibrotic diseases of the kidney, lung, liver, and heart; and an anti-inflammatory dual Semicarbazide-Sensitive Amine Oxidase (SSAO)/ Monoamine oxidase B (MAOB) inhibitor targeting Duchenne Muscular Dystrophy.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Pharmaxis Ltd is -62%, which is in line with its 3-year median of -62%.
Over the last 3 years, Pharmaxis Ltd’s Net Margin has increased from -111.1% to -62%. During this period, it reached a low of -111.1% on May 30, 2020 and a high of -13% on Jun 30, 2021.
